摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-N-(2-methylpropanoyl)-1-phenylethylamine | 92981-53-8

中文名称
——
中文别名
——
英文名称
(R)-N-(2-methylpropanoyl)-1-phenylethylamine
英文别名
(R)-N-(1-phenylethyl)isobutyramide;2-methyl-N-[(1R)-1-phenylethyl]propanamide
(R)-N-(2-methylpropanoyl)-1-phenylethylamine化学式
CAS
92981-53-8
化学式
C12H17NO
mdl
——
分子量
191.273
InChiKey
MXOQZZOTALYMAG-SNVBAGLBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    29.1
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

  • 作为产物:
    描述:
    R(+)-alpha-甲基苄胺异丁酸酐4-二甲氨基吡啶三乙胺 作用下, 以 二氯甲烷甲醇氯仿 为溶剂, 以91%的产率得到(R)-N-(2-methylpropanoyl)-1-phenylethylamine
    参考文献:
    名称:
    基于开环复分解聚合的可循环磁酰化试剂
    摘要:
    据报道,一种操作简单的方法是利用碳包覆的金属纳米颗粒作为可循环利用的载体来酰化胺。高磁性碳包覆的钴(Co / C)和铁(Fe / C)纳米珠通过“点击”反应通过降冰片烯标签(Nb-tag)功能化,然后使用Grubbs-II催化剂进行表面活化,然后接枝酰化N-羟基琥珀酰亚胺ROMPgels(ROMP =开环复分解聚合)。高负荷(高达2.6 mmol g -1杂化材料用于各种伯胺和仲胺的酰化反应。在快速倾析和简单蒸发溶剂后,分离出的产品具有高收率(86-99%)和出色的纯度(通过NMR光谱均大于95%)。废树脂成功地被酰氯,酸酐和羧酸重新酰化,并可以连续使用多达五个周期,而活性却没有显着降低。
    DOI:
    10.1002/cssc.201200453
点击查看最新优质反应信息

文献信息

  • Kinetic resolution of amines with enantiopure 3-N,N-diacylaminoquinazolin-4(3H)-ones
    作者:Al-Sehemi, Abdullah G.、Atkinson, Robert S.、Fawcett, John
    DOI:10.1039/b105917n
    日期:2002.1.7
    The title compounds (DAQs) are chiral when the two N-acyl groups are different because of the absence of rotation around the N–N bond (a chiral axis). Enantiopure DAQs have been obtained by incorporation of a chiral centre in enantiopure form either into the substituent at the Q2-position or into one of the N-acyl groups, or into both, followed by separation of diastereoisomers. This separation is unnecessary in one case because conversion of the N-monoacylaminoquinazolinone (MAQ) into the DAQ is completely diastereoselective. Neither is separation of diastereoisomers necessary with 3-[N,N-di-(S)-2-acetoxypropanoylamino]-2-diphenylmethylquinazolin-4(3H)-one 37a: this DAQ 37a has its N–N bond rendered a chiral axis by the bias in its imide moiety wholly in favour of one exo/endo conformation.The high chemoselectivity exhibited by N,N-diacetyl- or N,N-dibenzoylaminoquinazolinones in reaction with the less hindered of two secondary amines (pyrrolidine in the presence of 1 eq. of piperidine) has a stereoselective counterpart: reaction of the above enantiopure DAQs enantioselectively with racemic amines leading to kinetic resolution. Using 1 eq. of DAQ and 2 eq. of amine, both the derivatised and unreacted amine enantiomers are recovered with high enantiomeric excess (ee) (better than 90% ee in some cases). Some of the higher ees are found in the recovered amides where non-chemoselective attack on both N-acyl groups of the DAQ has occurred: from the opposite configurations of the amine component in the two amides and from the low enantiopurity of the recovered unreacted amine, reaction of each of the N-acyl groups with complementary enantiomers of the amine is occurring (parallel kinetic resolution).Although higher ees are, in general, obtained using secondary amines, high ees are obtained in some cases using 1-phenylethylamine and, in particular, amino acid esters (valine and alanine).The sense of enantioselectivity in the reactions of these DAQs with amines is controlled by the configuration of the N–N axis: replacing the Q group in an N-(S)-2-acetoxypropanoyl-N-acetyl-bearing DAQ by phthalimide, thus eliminating the N–N chiral axis, drastically reduces the level of kinetic resolution.
    标题化合物(DAQs)在两个N-酰基团不同时是手性的,因为N-N键(一个手性轴)缺乏旋转。通过将手性中心以手性形式引入Q2-位点的取代基或其中一个N-酰基团,或两者中,随后分离diastereoisomers,得到了纯对映体的DAQs。在一个情况下,这种分离是不必要的,因为将N-单酰胺基喹唑啉酮(MAQ)转化为DAQ是完全立体选择性的。对于3-[N,N-di-(S)-2-乙酰氧基丙酰胺基]-2-二苯甲基喹唑啉-4(3H)-酮37a,也不需要分离diastereoisomers:这个DAQ 37a通过其亚胺部分的偏向完全倾向于一个exo/endo构象,使其N-N键成为一个手性轴。N,N-二乙酰基或N,N-二苯甲酰氨基喹唑啉酮在与两个次级胺中较少受到阻碍的胺(在存在1 eq.的哌啶的情况下使用吡咯烷)反应时表现出高度的化学选择性,这在立体选择性上有对应:上述纯对映体的DAQs与外消旋胺反应,导致动力学拆分。使用1 eq.的DAQ和2 eq.的胺,衍生化的和未反应的胺对映体都以高对映体过量(ee)回收(在一些情况下优于90% ee)。在一些回收的酰胺中发现较高的ee,其中非化学选择性地攻击DAQ的两个N-酰基团:从两个酰胺中胺组分的相反构型和回收的未反应胺的低对映纯度,每个N-酰基团与胺的互补对映体反应(并行动态拆分)。尽管通常使用次级胺得到较高的ee,但在某些情况下使用1-苯乙胺,特别是氨基酸酯(缬氨酸和丙氨酸)得到高ee。这些DAQs与胺反应的对映选择性的方向受N-N轴配置的控制:在带有N-(S)-2-乙酰氧基丙酰基-N-乙酰基的DAQ中,通过用邻苯二甲酰亚胺替换Q组,从而消除N-N手性轴,显著降低了动力学拆分的水平。
  • Tricycloundecane compounds useful as modulators of nuclear hormone receptor function
    申请人:Balog Aaron James
    公开号:US20070088029A1
    公开(公告)日:2007-04-19
    Tricycloundecanes compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds are disclosed.
    三环十一烷化合物,以及在治疗核激素受体相关疾病如癌症和免疫紊乱中使用这些化合物的方法,以及含有这些化合物的药物组合物被披露。
  • Substituted pyrazoles as p38 kinase inhibitors
    申请人:Naraian S. Ashok
    公开号:US20070078146A1
    公开(公告)日:2007-04-05
    A class of pyrazole derivatives is described for use in treating p38 kinase medicated disorders. Compounds of particular interest are defined by Formula IA wherein R 1 , R 2 , R 3 and R 4 are as described in the specification.
    描述了一类吡唑衍生物,用于治疗p38激酶介导的疾病。特别感兴趣的化合物由公式IA定义,其中R1、R2、R3和R4如规范中所述。
  • DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
    申请人:Kowalski Jennifer A.
    公开号:US20120178734A1
    公开(公告)日:2012-07-12
    Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    6,7-二氢-5H-咪唑[1,2-a]咪唑-3-羧酸酰胺的衍生物对CAM和白细胞整合素的相互作用具有良好的抑制作用,因此在治疗炎症性疾病方面具有用途。
  • NOVEL JNK INHIBITORS
    申请人:Reddy Panduranga Adulla P.
    公开号:US20100298314A1
    公开(公告)日:2010-11-25
    Disclosed are substituted imidazo[1,2-a]pyridines, imidazo[1,2-a]pyrazines, imidazo[1,2-c]pyrimidines and imidazo[1,2-d]triazines compounds of the formula: (1.0) Also disclosed are methods for treating JNK1 and ERK mediated diseases using the compounds of formula 1.0.
    本发明涉及代替的咪唑[1,2-a]吡啶,咪唑[1,2-a]吡嗪,咪唑[1,2-c]嘧啶和咪唑[1,2-d]三嗪化合物,其化学式为:(1.0)。本发明还涉及使用化合物1.0治疗JNK1和ERK介导的疾病的方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐